MiCareo MiSelect R II & MiCount: Precision in Rare Cell Analysis MiCareo’s MiSelect R II and MiCount systems offer cutting-edge solutions for rare cell detection and analysis, designed for both clinical diagnostics and academic research. Innovative Technology ．eDAR Technology: Uses Ensemble Decision Aliquot Ranking (eDAR) for ultra-sensitive, high-purity isolation of rare cells, including circulating tumor cells (CTCs), immune cells, and endothelial progenitor cells (EPCs). ．High Sensitivity & Specificity: Capable of detecting 1 rare cell among billions, outperforming conventional flow cytometry or magnetic-based methods. ．Automated Workflow: Reduces human error and ensures reproducibility with fully automated target cell enrichment, staining, imaging, and analysis. ．Multi-Biomarker Detection: Enables analysis of up to 13 biomarkers per single cell, facilitating in-depth cellular characterization. Ideal Applications ．Clinical Use: Supports liquid biopsy-based diagnostics, cancer monitoring, and immunotherapy assessment (e.g., CAR-T therapy). ．Research & Drug Development: Ideal for biomarker discovery, cell therapy studies, and tumor-immune cell interaction analysis. ．Cardiovascular & Autoimmune Studies: Detects endothelial dysfunction, aiding in risk assessment for coronary artery disease. Solving Key Challenges ．Non-Invasive Testing: Eliminates the need for tissue biopsies by using a simple blood draw. ．Real-Time Monitoring: Enables dynamic tracking of disease progression and treatment response. ．High-Purity Rare Cell Retrieval: Allows downstream applications such as genetic sequencing, mutation analysis, and cell culture. ．Tiny amount of samples needed: Solve the problem of insufficient blood volume in model animals and difficulty in continuous analysis. MiCareo is seeking global distributors to bring these advanced technologies to healthcare and research institutions worldwide.